Osteonecrosis of the jaw



Bisphosphonates are effective therapy for osteoporosis, Paget’s disease, and metastatic bone disease. Generally, the side effects of bisphosphonates are minimal. Recently, an uncommon adverse reaction affecting the maxilla or mandible, called osteonecrosis of the jaw, has been reported, especially in those patients receiving high doses of bisphosphonates in the oncology setting. Regarding doses used to treat osteoporosis, clinicians must keep the very small potential absolute risk of jaw osteonecrosis in perspective and consider it in relation to the demonstrated benefit of bisphosphonates. Still, in a very small number of patients taking bisphosphonates, intractable, painful, nonhealing exposed bone may occur following dental extractions or denture irritation.

References and Recommended Reading

  1. 1.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527–534.PubMedCrossRefGoogle Scholar
  2. 2.
    Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115–1117.PubMedCrossRefGoogle Scholar
  3. 3.
    Carter GD, Goss AN: Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003, 48:268.PubMedGoogle Scholar
  4. 4.
    Khosla S, Burr D, Cauley J, et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479–1491.PubMedCrossRefGoogle Scholar
  5. 5.
    Black DM, Delmas PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809–1821.PubMedCrossRefGoogle Scholar
  6. 6.
    Yarom N, Yahalom R, Shoshani Y, et al.: Osteonecrosis of the jaw induced by orally administered bisphsphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis Int 2007, 18:1363–1370.CrossRefGoogle Scholar
  7. 7.
    Cheng A, Mavrokokki A, Carter G, et al.: The dental implications of bisphosphonates and bone disease. Aust Dent J 2005, 50(Suppl 2):S4–S13.PubMedCrossRefGoogle Scholar
  8. 8.
    Marunick M, Miller R, Gordon S: Adverse oral sequelae to bisphosphonate administration. J Mich Dent Assoc 2005, 87:44–49.PubMedGoogle Scholar
  9. 9.
    Migliorati CA: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003, 21:4253–4254.PubMedCrossRefGoogle Scholar
  10. 10.
    Purcell P, Boyd I: Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005, 182:417–418.PubMedGoogle Scholar
  11. 11.
    Farrugia M, Summerlin DJ, Krowiak E, et al.: Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006, 116:115–120.PubMedCrossRefGoogle Scholar
  12. 12.
    Chang J: 2004 Food and Drug Administration Postmarketing Review. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.pdf. Accessed on January 18, 2008.
  13. 13.
    Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxill Surg 2007, 65:415–423.CrossRefGoogle Scholar
  14. 14.
    Starck W, Epker BN: Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 1995, 10:74–78.PubMedGoogle Scholar
  15. 15.
    Hoefert S, Eufinger H: Necrosis of the jaws under bisphosphonate therapy. Orthopade 2005, 35:204–210.CrossRefGoogle Scholar
  16. 16.
    Najm S, Lysitsa S, Carrel JP, et al.: Osteonecrose des maxillaries chez des patients traits par bisphosphonates. J Presse Med 2005, 34:1073–1077.Google Scholar
  17. 17.
    Pozzi S, Marcheselli R, Sacchi S, et al.: Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood 2005, 106:A5057.Google Scholar
  18. 18.
    Felsenberg D, Hoffmeister B, Michael Amling M: Bisphosphonat therapie assoziierte. Kiefernekrosen Deutsches Arzteblatt 2006, 46:A3078–A3080.Google Scholar
  19. 19.
    Hoff AO, Toth, B, Altunag K, et al.: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Bone Miner Res 2005, 20(Suppl 1):1218.Google Scholar
  20. 20.
    Lyles KW, Colon-Emeric CS, Magaziner JS, et al.: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 356:1799–1809. [Comment in: N Engl J Med 2007, 357:1861–1862.]CrossRefGoogle Scholar
  21. 21.
    Sambrook PN, Olver I, Goss A: BP and osteonecrosis if the jaw. Aust Fam Physic 2006, 35:801–803.Google Scholar
  22. 22.
    Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J: Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007, 18:556–560.PubMedCrossRefGoogle Scholar
  23. 23.
    Woo SB, Hellstein, JW, Kalmer JR: Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006, 144:753–761. [Erratum in: Ann Intern Med 2006, 145:235. Comment in: Ann Intern Med 2006, 145:791–792; author reply 792. Ann Intern Med 2006, 145:791; author reply 792. Nat Clin Pract Endocrinol Metab 2006, 2:662–663.]PubMedGoogle Scholar
  24. 24.
    Hewitt C, Farah CS: Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Path Med 2007, 36:319–328.Google Scholar
  25. 25.
    Fournier P, Boissier S, Filleur S, et al.: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538–6544.PubMedGoogle Scholar
  26. 26.
    Aguirre JI, Vanegas SM, Altman MK, et al.: Alendronate impairs angiogenesis and bone formation during the early stages of bone healing in an animal model for osteonecrosis of the jaw. J Bone Miner Res 2007, 22(S1):1265.Google Scholar
  27. 27.
    Ardine M, Generali D, Donadio M, et al.: Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006, 17:1336–1337.PubMedCrossRefGoogle Scholar
  28. 28.
    Okada H, Murakami S: Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998, 9:248–266.PubMedCrossRefGoogle Scholar
  29. 29.
    Reid I: Is bisphosphonate associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007, 41:318–320.PubMedCrossRefGoogle Scholar
  30. 30.
    Khamaisi M, Regev E, Yarom N, et al.: Possible association between diabetes and bisphosphonate-related jaw osteone-crosis. J Clin Endocrinol Metab 2007, 92:1172–1175.PubMedCrossRefGoogle Scholar
  31. 31.
    Polizzotto MN, Cousins V, Schwerer A: Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 2006, 132:114.PubMedCrossRefGoogle Scholar
  32. 32.
    Phal PM, Myall RW, Assael LA, Weissman JL: Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. Amer J Neuroradiol 2007, 28:1139–1145.CrossRefGoogle Scholar
  33. 33.
    Marx RE, Cillo Jr JE, Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007, 65:2397–2410.PubMedCrossRefGoogle Scholar
  34. 34.
    Migliorati C, Casiglia J, Epstein J, et al.: Managing the care of patients with bisphosphonate associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005, 136:1658–1668. [Erratum in: J Am Dent Assoc 2006, 137:26. Comment in: J Am Dent Assoc 2006, 137:441. J Am Dent Assoc 2006, 137:441–442; author reply 442–443. J Am Dent Assoc 2006, 137:443–444; author reply 444–445. J Am Dent Assoc 2006, 137:584; discussion 584.]PubMedGoogle Scholar
  35. 35.
    Magopoulos C, Karakinaris G, Telioudis Z, et al.: Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 2007, 28:158–163.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Kolling Institute of Medical ResearchUniversity of Sydney (E25) Royal North Shore Hospital, Saint LeonardsSydneyAustralia

Personalised recommendations